Irbesartan Amarox (Irbesartan)

Irbesartan blocks angiotensin II type 1 (AT1) receptors, preventing the hormone from causing vasoconstriction and stimulating aldosterone release. This results in relaxed blood vessels, reduced peripheral resistance, and decreased sodium‑water retention, which together lower blood pressure and protect kidney function.

The appropriate dose of Irbesartan Amarox is determined by the prescribing clinician based on the individual’s blood‑pressure targets, kidney function, and overall health status. Dosage may be adjusted during therapy to achieve optimal control.

Safety data for irbesartan during pregnancy are limited, and the drug is generally avoided in the second and third trimesters because of potential fetal toxicity. Breast‑feeding mothers should consult a healthcare professional, as irbesartan can be excreted in milk.

To place an order, submit an enquiry on the Irbesartan Amarox product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly on vascular smooth‑muscle calcium channels, providing an alternative mechanism for patients who cannot tolerate other agents.

Irbesartan Amarox should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability throughout its shelf‑life.

Irbesartan is taken orally, usually once daily. It can be swallowed with or without food; however, consistent administration with respect to meals helps maintain steady blood‑level concentrations.

Serious adverse events include angio‑edema (swelling of the face, lips or tongue), severe hypotension, marked hyperkalaemia, and acute kidney injury. Patients should seek immediate medical attention if they experience swelling, difficulty breathing, sudden dizziness, or a rapid decline in kidney function.

Irbesartan is contraindicated in individuals with known hypersensitivity to irbesartan or any other ARB, in patients with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for patients with severe renal artery stenosis or those taking certain potassium‑increasing agents.